Close Menu

NEW YORK – With a new CEO at the helm, HiberGene is refocusing its efforts toward research and development. The Dublin, Ireland-based firm is using low cost as the rubric in its development of a new point-of-care molecular diagnostics instrument that will be based on its core technologies.

Simona Esposito replaced CEO and co-founder Brendan Farrell, who retired last year, in April, after joining HiberGene as chief commercial officer nine months ago.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.